RDTCF (Rapid Dose Therapeutics) Research & Development: $0.05 Mil (TTM As of Nov. 2025)


RDTCF Rapid Dose Therapeutics Corp RDTCF
27 GF Score
Price $0.08
GF Value $0.30
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Rapid Dose Therapeutics Research & Development?

Rapid Dose Therapeutics RDTCF -11.11% 27 Research & Development is $0.05 Mil as of Nov. 2025. GuruFocus rates RDTCF with a GF Score™ of 27/100 and a GF Value™ of $0.30 (Possible Value Trap). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Rapid Dose Therapeutics's Research & Development for the three months ended in Nov. 2025 was $0.01 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Nov. 2025 was $0.05 Mil.

Rapid Dose Therapeutics  (OTCPK:RDTCF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Rapid Dose Therapeutics Research & Development Related Terms

Rapid Dose Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Rapid Dose Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapid Dose Therapeutics Research & Development Chart

Rapid Dose Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.28 0.07 0.32 0.10

Rapid Dose Therapeutics Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 -0.01 0.01 0.01
RDTCF
27GF Score
Rapid Dose Therapeutics Corp RDTCF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rapid Dose Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.05 Mil mean?
Rapid Dose Therapeutics (RDTCF) has a Research & Development of $0.05 Mil as of Nov. 2025. Research and development expense is the total cost for research and development activities. View historical data on Rapid Dose Therapeutics and its competitors.
Is Rapid Dose Therapeutics' Research & Development too high?
Rapid Dose Therapeutics' current Research & Development is $0.05 Mil. Overall, Rapid Dose Therapeutics has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rapid Dose Therapeutics' Research & Development compare to VRTX and REGN?
Rapid Dose Therapeutics' Research & Development of $0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Rapid Dose Therapeutics and its competitors. Rapid Dose Therapeutics's current Research & Development is $0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Dose Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Rapid Dose Therapeutics (RDTCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.30, compared to a current price of $0.08 — trading 73.3% below its estimated fair value. The current Research & Development is $0.05 Mil. Rapid Dose Therapeutics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Rapid Dose Therapeutics (RDTCF), the current Research & Development is $0.05 Mil as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rapid Dose Therapeutics (RDTCF) Overvalued in 2026?

Based on GuruFocus' analysis, Rapid Dose Therapeutics stock appears to be undervalued. The current stock price of $0.08 is trading 73.3% below its estimated GF Value™ of $0.30. GuruFocus considers Rapid Dose Therapeutics to be Possible Value Trap.

Key valuation signals for RDTCF:

  • Research & Development: $0.05 Mil
  • GF Value™: $0.30 vs. price of $0.08 (73.3% below fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the RDTCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rapid Dose Therapeutics Business Description

Other Exchanges DOSE:Canada
Address 1121 Walkers Line, Unit 3a, Burlington, ON, CAN, L7N 2G4
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
27GF Score

Get the complete analysis for RDTCF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price
$0.30
GF Value